444 Presence of AR-V7 splice variant or AR C terminal loss in the CTCs of mCRPC patients identifies patients with improved PSA response with taxanes over androgen receptor signaling directed therapies (ARS Rx)

H.I Scher,J Kelvin,D Lu,J Louw,D Packer,R Bambury,D Rathkopf,N Schreiber,R Brennan,N Prigozhina,D Brown,A Jendrisak,L Dugan,M Landers,F Lee,M Fleisher,D Marrinucci,R Dittamore

doi:10.1016/s0959-8049(16)30278-7

444 Presence of AR-V7 splice variant or AR C terminal loss in the CTCs of mCRPC patients identifies patients with improved PSA response with taxanes over androgen receptor signaling directed therapies (ARS Rx)

H.I Scher, J Kelvin + Show 16 more

https://doi.org/10.1016/s0959-8049(16)30278-7

Copy DOI

Journal: European Journal of Cancer

Publication Date: Sep 1, 2015

#Terminal Loss #AR-V7 Splice Variant + Show 7 more

Abstract
Full-Text
Similar Papers

Abstract

444 Presence of AR-V7 splice variant or AR C terminal loss in the CTCs of mCRPC patients identifies patients with improved PSA response with taxanes over androgen receptor signaling directed therapies (ARS Rx)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Similar Papers

Paper Title

Journal

Date

Author

View more papers

More From: European Journal of Cancer

Paper Title

Journal

Date

Author

View more papers

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.